CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to GSK

Umeclidinium/Vilanterol 62.5/25 mcg

Phase 3
GSK plc (GSK)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Pulmonary Disease, Chronic Obstructive

View Full Landscape
Drug Information

Target Indication

Pulmonary Disease, Chronic Obstructive

Clinical Trial

NCT01899742

Last updated: 1/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.